Πέμπτη 12 Οκτωβρίου 2017

Phase III Study of Simultaneous Integrated Boost Radiotherapy (SIB-IMRT) With or Without Concurrent Chemotherapy for Locally Advanced Esophageal Cancer - 3JECROG-P02

Condition:   Esophageal Neoplasms
Interventions:   Radiation: SIB-IMRT;   Drug: Paclitaxel;   Drug: Platinum-Based Drug
Sponsors:   Chinese Academy of Medical Sciences;   Hebei Medical University Fourth Hospital;   Tianjin Medical University Cancer Institute and Hospital;   Anyang Tumor Hospital;   The First Affiliated Hospital with Nanjing Medical University;   Affiliated Hospital of Hebei University;   Fujian Cancer Hospital;   Sichuan Cancer Hospital and Research Institute
Recruiting

from #ORL via a.lsfakia on Inoreader http://ift.tt/2kJ7zii
via IFTTT

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου